Moderna faces weak post-pandemic vaccine demand and financial struggles, with limited near-term catalysts. Click here to read ...

The number of biopharma professionals let go has increased year over year for three straight months. In July, nearly 8,000 ...

One particular S&P 500 biotech continues to stink out our writer's Stocks and Shares ISA. Is it time he chucked in the towel? The post This S&P 500 stock could surge 55% in just 12 months, according ...

CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission ...

Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...

MCLEAN, VA / ACCESS Newswire / July 31, 2025 / Gladstone Capital Corporation (Nasdaq:GLAD) announces the following event: ...

CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal ...

A strategy of selecting stocks based on rapid revenue growth has outperformed the broad market over the decades MarketWatch's Brett Arends covered research showing that a combination of looking back ...

Moderna, Inc.'s Q2 2025 earnings highlight a steep revenue decline post-pandemic, with just $0.1bn in revenue and a $(0.8bn) ...

In a note to employees on Thursday, Moderna Inc. said it was laying off about 10% of its global workforce as part of the ...

Nevertheless, Moderna has lowered its revenue guidance for the year by $300 million. The company now expects to generate ...

The layoffs are part of an ongoing effort to reduce operating costs amid government and competitive challenges to its vaccine ...